Biometrical journal. Biometrische Zeitschrift
-
To assess the current dynamics of an epidemic, it is central to collect information on the daily number of newly diseased cases. This is especially important in real-time surveillance, where the aim is to gain situational awareness, for example, if cases are currently increasing or decreasing. Reporting delays between disease onset and case reporting hamper our ability to understand the dynamics of an epidemic close to now when looking at the number of daily reported cases only. ⋯ We provide methodological details of the developed approach, illustrate results based on data of the current pandemic, and evaluate the model based on synthetic and retrospective data on COVID-19 in Bavaria. Results of our nowcasting are reported to the Bavarian health authority and published on a webpage on a daily basis (https://corona.stat.uni-muenchen.de/). Code and synthetic data for the analysis are available from https://github.com/FelixGuenther/nc_covid19_bavaria and can be used for adaption of our approach to different data.
-
We analyse the temporal and regional structure in mortality rates related to COVID-19 infections, making use of the openly available data on registered cases in Germany published by the Robert Koch Institute on a daily basis. Estimates for the number of present-day infections that will, at a later date, prove to be fatal are derived through a nowcasting model, which relates the day of death of each deceased patient to the corresponding day of registration of the infection. ⋯ The analysis of death counts contributes to a better understanding of the spread of the disease while being, to some extent, less dependent on testing strategy and capacity in comparison to infection counts. The proposed approach and the presented results thus provide reliable insight into the state and the dynamics of the pandemic during the early phases of the infection wave in spring 2020 in Germany, when little was known about the disease and limited data were available.
-
In network meta-analysis (NMA), treatments can be complex interventions, for example, some treatments may be combinations of others or of common components. In standard NMA, all existing (single or combined) treatments are different nodes in the network. However, sometimes an alternative model is of interest that utilizes the information that some treatments are combinations of common components, called component network meta-analysis (CNMA) model. ⋯ All parameters are estimated using weighted least squares regression. We illustrate the application of CNMA models using an NMA of treatments for depression in primary care. Moreover, we show that these models can even be applied to disconnected networks, if the composite treatments in the subnetworks contain common components.
-
The conduct of phase II and III programs is costly, time-consuming and, due to high failure rates in late development stages, risky. There is a strong connection between phase II and III trials as the go/no-go decision and the sample size chosen for phase III are based on the results observed in phase II. An integrated planning of phase II and III is therefore reasonable. ⋯ Optimal phase II sample sizes and go/no-go decision rules are provided for time-to-event outcomes and cases, where at least one, two, or three phase III trials need to be successful. Different drug development program strategies (e.g. one large vs. two phase III trials) are compared within these different cases. Application to practical examples typically met in oncology trials illustrates the proposed method.